Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue 3, 2006, Pages 714-720

  Ma, Brigette B Y ^a   King, Ann ^a   Lo, Y M Dennis ^a   Yau, Y Y ^b   Zee, Benny ^c   Hui, Edwin P ^a   Leung, Sing F ^a   Mo, Frankie ^a   Kam, Michael K ^a   Ahuja, Anil ^a   Kwan, Wing H ^a   Chan, Anthony T C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b Hong Kong Baptist Hospital   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Magnetic resonance imaging; Nasopharyngeal carcinoma; Plasma Epstein Barr virus DNA; Positron emission tomography

Indexed keywords

BIOMARKERS; COMPUTERIZED TOMOGRAPHY; DNA; MAGNETIC RESONANCE IMAGING; METABOLISM; POSITRON EMISSION TOMOGRAPHY; VIRUSES;

CELL FREE PLASMAS; NASOPHARYNGEAL CARCINOMA; PLASMA EPSTEIN-BARR VIRUS DNA; PROGNOSTIC MARKERS;

TUMORS;

FLUORODEOXYGLUCOSE F 18; VIRUS DNA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DNA DETERMINATION; EPSTEIN BARR VIRUS; FEMALE; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANK SUM TEST; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

ADULT; AGED; ALGORITHMS; CLINICAL TRIALS, PHASE II; DNA, VIRAL; FEMALE; FLUORODEOXYGLUCOSE F18; HERPESVIRUS 4, HUMAN; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RANDOMIZED CONTROLLED TRIALS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 33749030703     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.05.064     Document Type: Article

References (42)

1. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12 (2002) 431-441
2. Pathmanathan R., Prasad U., Sadler R., et al. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 333 (1995) 693-698
3. Lo Y.M., Chan L.Y., Lo K.W., et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 59 (1999) 1188-1191
4. Chan A.T., Ma B., Lo D., et al. A phase II study of neoadjuvant taxol and carboplatin followed by concurrent cisplatin-radiotherapy in locoregionally advanced nasopharyngeal carcinoma with EBV DNA monitoring. J Clin Oncol 22 (2004) 1-8
5. Lo Y.M., Leung S.F., Chan L.Y., et al. Plasma cell-free Epstein-Barr virus DNA quantitation in patients with nasopharyngeal carcinoma. Correlation with clinical staging. Ann N Y Acad Sci 906 (2000) 99-101
6. Lo Y.M., Chan A.T., Chan L.Y., et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 60 (2000) 6878-6881
7. Chan A.T., Lo Y.M., Zee B., et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 94 (2002) 1614-1619
8. Chan K.C., Chan A., Leung S., et al. Investigation into the origin and tumoral mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma. Clin Chem 51 (2005) 2192-2195
9. Jacob R., Welkoborsky H.J., Mann W.J., et al. [Fluorine-18]fluorodeoxyglucose positron emission tomography, DNA ploidy and growth fraction in squamous-cell carcinomas of the head and neck. J Otorhinolaryngol Relat Spec 63 (2001) 307-313
10. Bos R., van Der Hoeven J.J., van Der Wall E., et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20 (2002) 379-387
11. Kurokawa T., Kawahara K., Tsuchida T., et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer 109 (2004) 926-932
12. Vesselle H., Pugsley J.M., Li M., et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 6 (2000) 3837-3844
13. Folpe A.L., Sprouse J.T., Conrad E.U.3r., et al. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 6 (2000) 1279-1287
14. Sakurai H., Suzuki Y., Nonaka T., et al. FDG-PET in the detection of recurrence of uterine cervical carcinoma after radiation therapy-tumor volume and FDG uptake value. Gynecol Oncol 100 (2006) 601-607
15. Buck A.K., Schirrmeister H., Mattfeldt T., et al. Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 31 Suppl 1 (2004) S80-S87
16. Gambhir S.S. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2 (2002) 683-693
17. Kao C.H., Chang Lai S.P., Chieng P.U., et al. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography. J Clin Oncol 16 (1998) 3550-3555
18. Tsai M.H., Kao C.H., Shen Y.Y., et al. Detection of recurrent nasopharyngeal carcinomas with positron emission tomography using 18-fluoro-2-deoxyglucose in patients with indeterminate magnetic resonance imaging findings after radiotherapy. J Cancer Res Clin Oncol 128 (2002) 279-282
19. 18F-FDG PET in recurrent or metastatic nasopharyngeal carcinoma. J Nucl Med 46 (2005) 770-774
20. Schoder H., Gonen M., Kraus D., et al. Head and neck cancer: Clinical usefulness and accuracy of PET/CT image fusion. Radiology 231 (2004) 65-72
21. Cohade C., and Wahl R. Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography-clinical use, interpretation methods, diagnostic improvements. Semin Nucl Med 33 (2003) 228-237
22. American Joint Committee on Cancer (AJCC). Cancer staging handbook. 6th ed. (2002), Springer-Verlag, New York
23. King A.D., Lam W., Leung S.F., et al. MRI of local disease in nasopharyngeal carcinoma: Tumour extent vs tumour stage. Br J Radiol 72 (1999) 734-741
24. King A.D., Ahuja A., Leung S.F., et al. Neck node metastases from nasopharyngeal carcinoma: MR imaging of patterns of disease. Head Neck 22 (2000) 275-281
25. Antoch G., Saoudi N., Kuehl H., et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: Comparison with CT and PET. J Clin Oncol 22 (2004) 4357-4368
26. Yau Y.Y., Chan W.S., Tam Y.M., et al. Application of intravenous contrast in PET/CT: Does it really introduce significant attenuation correction error?. J Nucl Med 46 (2005) 283-291
27. Chan A., Hui E., Ma B., et al. A randomized phase II study of concurrent cisplatin-radiotherapy (RT) with or without neoadjuvant chemotherapy using docetaxel (Taxotere) and cisplatin in advanced nasopharyngeal carcinoma (NPC). Proc Am Soc Clin Oncol (2005) Abstr 5544.
28. Johnson P.J., and Lo Y.M. Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem 48 (2002) 1186-1193
29. Lit L.C., Chan K.C., Leung S.F., et al. Distribution of cell-free and cell-associated Epstein-Barr virus (EBV) DNA in the blood of patients with nasopharyngeal carcinoma and EBV-associated lymphoma. Clin Chem 50 (2004) 1842-1845
30. Chan K.C., Chan A., Lei K., et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 63 (2003) 2028-2032
31. Chua D.T., Sham J., Kwong D.L., et al. Volumetric analysis of tumor extent in nasopharyngeal carcinoma and correlation with treatment outcome. Int J Radiat Oncol Biol Phys 39 (1997) 711-719
32. Sze W.M., Lee A., Yau T.K., et al. Primary tumor volume of nasopharyngeal carcinoma: Prognostic significance for local control. Int J Radiat Oncol Biol Phys 59 (2004) 21-27
33. Kim J.H., and Lee J. Prognostic value of tumor volume in nasopharyngeal carcinoma. Yonsei Med J 46 (2005) 221-227
34. Daisne J.F., Weynand B., Lonneux M., et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: Comparison of CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 233 (2004) 93-100
35. Rasch C., Keus R., Pameijer F.A., et al. The potential impact of CT-MRI matching on tumor volume delineation in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 39 (1997) 841-848
36. Jahr S., Englisch S., Hardt D., et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61 (2001) 1659-1665
37. Nagata S. Apoptotic DNA fragmentation. Exp Cell Res 256 (2000) 12-18
38. 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 46 (2005) 658-666
39. Vesselle H., Grierson J., Muzi M., et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: Correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 8 (2002) 3315-3323
40. 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx. J Nucl Med 46 (2005) 405-410
41. 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes?. Eur J Nucl Med Mol Imaging 32 (2005) 541-548
42. Leung S.F., Chan A., Zee B., et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 98 (2003) 288-291